GlassScriptPhysician profile
Lacy J Voth
NPI 1578995379
$5,565.72
in general payments reported to CMS, 2019-2025
42 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,790 · 2022: $1,239 · 2023: $859 · 2024: $1,209 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,518 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,517.92 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $652.25 | 2021-2025 | |
| Novo Nordisk INC | $625.66 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $604.92 | 2021-2024 | Jardiance |
| Lilly USA, LLC | $387.64 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $336.36 | 2021-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $326.71 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.29 | 2021-2024 | Xifaxan, Trulance, Cycloset |
| Almatica Pharma LLC | $247.94 | 2021-2024 | Loreev Xr |
| Astrazeneca Pharmaceuticals LP | $211.33 | 2021-2024 | Farxiga, Airsupra |
| Mylan Specialty L.P. | $177.78 | 2022-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $133.48 | 2021-2025 | |
| Pfizer INC. | $122.15 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $116.05 | 2021-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $98.54 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $94.90 | 2021-2023 | Rexulti |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacy Voth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.